Xiangqian Kong
Papers
1
Total Citations
9
H-Index
1
About
Dr. Xiangqian Kong is a leading researcher in non-invasive cancer diagnostics, with a primary focus on the development of cost-effective, liquid biopsy-based tools for early lung cancer detection. His most significant contribution is the pioneering work on plasma protein functional effector sncRNAs (pfeRNAs), demonstrating their utility as non-invasive biomarkers to differentiate benign, suspicious, and malignant pulmonary nodules. This breakthrough, detailed in his highly cited 2021 paper (9 citations), offers a promising alternative to invasive procedures, potentially transforming clinical decision-making for early-stage lung cancer patients. By addressing the critical challenge of distinguishing malignant nodules from benign ones, Dr. Kong’s research directly impacts patient outcomes, reducing unnecessary surgeries and enabling timely intervention. His work stands at the intersection of molecular biology and clinical oncology, showcasing a practical, scalable approach to precision medicine. With growing recognition for his innovative biomarker strategies, Dr. Kong continues to advance the field of non-invasive cancer testing, making him a key figure in the pursuit of accessible and accurate early cancer diagnostics.
Research Focus
Key Achievements
Top Papers
- 1